Related Experiment Videos
A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer
R V Iaffaioli1, A Tortoriello, G Facchini
1Istituto di Medicina Interna, Università di Cagliari, Italy.
British Journal of Cancer
|November 1, 1995
Abstract:
Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.